GlassScriptPhysician profile
Richard Breidenstein
NPI 1619672425
$2,224.47
in general payments reported to CMS, 2019-2025
16 companies · $1,394 in 2025
The $1,394 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $244 · 2024: $586 · 2025: $1,394.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,224.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,224.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $543.37 | 2024-2025 | |
| Emd Serono, INC. | $343.98 | 2025 | |
| Sk Life Science, INC. | $263.95 | 2024-2025 | Xcopri |
| Alexion Pharmaceuticals, INC. | $255.20 | 2023-2025 | Ultomiris |
| Ucb, INC. | $215.11 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Novartis Pharmaceuticals Corporation | $186.35 | 2024-2025 | |
| Mdd US Operations, LLC | $123.80 | 2023 | Gocovri |
| Eisai INC. | $53.98 | 2025 | |
| Acadia Pharmaceuticals INC | $53.61 | 2025 | Nuplazid |
| Genzyme Corporation | $45.12 | 2024 | |
| Biogen, INC. | $36.51 | 2025 | Vumerity |
| Neurocrine Biosciences, INC. | $31.27 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.53 | 2025 | Hyqvia |
| Lilly USA, LLC | $18.71 | 2025 | Amyvid, Kisunla |
| Genentech USA, INC. | $15.55 | 2025 | Ocrevus |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $15.43 | 2025 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Breidenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.